Amgen has agreed to a $74 million settlement with investors to resolve a lawsuit that alleged the company hid a $10.7 billion tax bill from the public and kept the company’s share price artificially high from July of 2020 to April of 2022.

With former Merck KGaA CEO Belén Garijo, M.D., Ph.D., now calling the shots at Sanofi, the French drugmaker continues to refine its executive roster, albeit with fewer high-profile C-suite departures now than earlier in the year.

Aerospace technology company Redwire—which has partnered with BMS and Eli Lilly to test drug development and manufacturing in space—has opened a new 30,000-square-foot research and microgravity payload development facility in Indiana.

Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has received a harsher reprimand from the U.S. FDA.

Novartis’ CEO remains unfazed by the threat of a newly approved oral PCSK9 inhibitor in Merck & Co.’s Lipfendra, doubling down on the long-term potential of his company’s injectable cholesterol drug, Leqvio.

Johnson & Johnson and AbbVie look set for a continued pharma ad spending battle for the second half of 2026 as the U.S. Big Pharma’s immunology drug Tremfya took the top spot for a second quarter in a row, according to data from iSpot.tv.